#Harpoon therapeutics stock trial#

Price Action: HARP shares are down 24.3% at $15.86 during the market session on the last check Friday.Harpoon's management will host a webcast and conference call today at 4 p.m.

2/89 patients discontinued treatment due to treatment-related AEs.Dose Limiting Toxicities (DLTs) were observed at doses ranging from 96 to 300ng/kg and did not limit escalation, and Maximum Tolerated Dose was not reached.CRS and transaminitis events were observed most often in Cycle 1, with diminished frequency and severity in subsequent cycles.

Treatment duration of over 24 weeks was observed in 15 of 74 (20%) of patients, including 8 of 17 (47%) chemo-naïve patients.

Antitumor activity included one confirmed partial response, PSA declines, and circulating tumor cell (CTC) reductions.

As of April 23, the data cutoff date, 89 patients have been dosed across 13 cohorts at fixed doses of 1.3 to 160 ng/kg and in step dosing cohorts up to 300ng/kg administered as a weekly intravenous infusion. What should I doIBRX Immunity 14.42 KNSA Kiniksa 14.67 ZIOP ZIOPHARM 2.81 ITOS ITeos Th 25.58 SNGX Sol.

HPN424 targets prostate-specific membrane antigen (PSMA) and is based on Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient's immune cells to kill tumor cells. Stock Price Forecast The 9 analysts offering 12-month price forecasts for Harpoon Therapeutics Inc have a median target of 8.00, with a high estimate of 16.00 and a low estimate of 7.00.

Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

#Harpoon therapeutics stock trial#

Harpoon Therapeutics Inc (NASDAQ:HARP) has announced interim data from the ongoing dose-escalation portion of a Phase 1/2a trial evaluating HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC).